GoodTaste
Key Member
- Joined
- Feb 19, 2016
- Member Type
- Student or Learner
- Native Language
- Chinese
- Home Country
- China
- Current Location
- China
The use of "give way to evidence" sounds odd to me because, if it (the antibodies of recovered COVID-19 patients) works, then it produces (rather than gives way) evidence.
Perhaps I've not correctly understood the meaning of "give way" - does the phrase mean "offer"/"produce" here?
===================
On 13 March, with the COVID-19 pandemic exploding and drugs elusive, Arturo Casadevall published what he considers “maybe the most important paper” of his long career. In The Journal of Clinical Investigation, the infectious disease specialist at Johns Hopkins University and Liise-anne Pirofski of Albert Einstein College of Medicine argued that one effective treatment might already be at hand: the blood plasma of people who have recovered from the disease, rich in antibodies against the virus. The strategy seems to have worked in other infections, the duo pointed out, and the infrastructure for collecting and administering plasma exists. The risks are known and comparatively low. “We recommend that institutions … begin preparations as soon as possible,” they wrote. “Time is of the essence.”
Ten weeks later, more than 16,000 patients at hundreds of U.S. hospitals have received the experimental therapy, and hope that it works could soon give way to evidence. A study of patients treated with serum at Mount Sinai Hospital in New York City, published as a preprint on 22 May, offers hints it may, as do other small studies elsewhere. But randomized controlled clinical trials (RCTs) that will give more definitive answers are still underway.
Source: Science [FONT="]May. 27, 2020[/FONT]
https://www.sciencemag.org/news/2020/05/can-plasma-covid-19-survivors-help-save-others
Perhaps I've not correctly understood the meaning of "give way" - does the phrase mean "offer"/"produce" here?
===================
On 13 March, with the COVID-19 pandemic exploding and drugs elusive, Arturo Casadevall published what he considers “maybe the most important paper” of his long career. In The Journal of Clinical Investigation, the infectious disease specialist at Johns Hopkins University and Liise-anne Pirofski of Albert Einstein College of Medicine argued that one effective treatment might already be at hand: the blood plasma of people who have recovered from the disease, rich in antibodies against the virus. The strategy seems to have worked in other infections, the duo pointed out, and the infrastructure for collecting and administering plasma exists. The risks are known and comparatively low. “We recommend that institutions … begin preparations as soon as possible,” they wrote. “Time is of the essence.”
Ten weeks later, more than 16,000 patients at hundreds of U.S. hospitals have received the experimental therapy, and hope that it works could soon give way to evidence. A study of patients treated with serum at Mount Sinai Hospital in New York City, published as a preprint on 22 May, offers hints it may, as do other small studies elsewhere. But randomized controlled clinical trials (RCTs) that will give more definitive answers are still underway.
Source: Science [FONT="]May. 27, 2020[/FONT]
https://www.sciencemag.org/news/2020/05/can-plasma-covid-19-survivors-help-save-others
